Auf dieser Website kommen Cookies zum Einsatz. Für weitere Informationen über Cookies, klicken Sie bitte auf den Link Datenschutz. Wenn Sie „Ok“ klicken und die Website weiter nutzen, gehen wir von Ihrem Einverständnis aus.

Cookies are used on this website. For more information about cookies, please click on the Privacy Policy link. If you click on "Ok" and continue to use the website, we assume your agreement.

GNA Biosolutions won the AACC Technology Award in Chicago 2018

Download: Press-ZIP (includes press release and photos)

GNA presented data from the company’s proprietary Pulse Controlled Amplification (PCA) technology, which allows for ultrafast (15 minutes or less), sample-to-result workflows.

Martinsried by Munich, August 2, 2018: GNA Biosolutions was named the winner of the American Association of Clinical Chemistry’s (AACC) Disruptive Technology Award competition, held on Monday evening at the 70th AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago, Illinois. The AACC Disruptive Technology Award recognizes innovative testing solutions that improve patient care through diagnostic performance or access to high-quality testing. GNA Biosolutions, a Munich based company in the Innovation- and Start-up Center for Biotechnology (IZB) also won the audience choice award.

GNA presented data from the company’s proprietary Pulse Controlled Amplification (PCA) technology, which allows for ultrafast (15 minutes or less), sample-to-result workflows even on challenging clinical matrices such as whole blood. After launching a first PCA instrument (Pharos V8) at the end of 2017, GNA now plans to launch a portable and low-cost sample-to-result platform for infectious disease molecular testing at the Point of Care.

The planned assay pipeline for GNA’s CLIA-waivable POC platform focuses on antimicrobial-resistant pathogens that are highly relevant causes of hospital acquired infections, as well as multi-drug resistant tuberculosis (MDR-TB), an emerging challenge and risk for global health. “We are honored to receive the Disruptive Technology Award from the AACC” said GNA Biosolutions co-founder and Managing Director Lars Ullerich. “Being recognized for our PCA technology is a proud moment for our whole team and we look forward to delivering it to the Point of Care.” The company is also engaged in strategic partnerships to bring PCA-enabled ultrafast sample-to-answer workflows to applications across multiple industries. PCA is uniquely scalable from single-sample applications at the POC, to high-throughput applications in centralized laboratories.

About GNA Biosolutions: GNA Biosolutions is a molecular technology company based in Germany. Our breakthrough technology, Pulse Controlled Amplification (PCA), transforms molecular testing by combining ultrafast nucleic acid amplification with intrinsic sample prep, to enable powerful solutions for the laboratory, on-site applications and the Point of Care. Our vision is to bring the power of molecular testing, from sample to answer, to everyone, everywhere. For more information, visit: www.gna-bio.com

Bildunterschrift:

Lars Ullerich, PhD, MBR, Managing Director Business Development GNA Biosolutions wins the AACC´s Disruptive Technology Award in Chicago

Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich

The Fördergesellschaft IZB mbH, founded in 1995, is a subsidiary of the Free State of Bavaria. It is the operating company of the innovation and incubator centers for biotechnology in Planegg-Martinsried and Freising-Weihenstephan and has developed into a renowned biotechnology center that belongs to the top ten in the world. On 26,000 m², more than 50 biotech companies with over 600 employees are currently located. It is working on the development of medicines for the most serious diseases, such as cancer, Alzheimer's disease and various autoimmune diseases - and there are already many successes. At the IZB Freising-Weihenstephan - 15 minutes from the airport - scientists are working  on developments in the field of life science. An essential criterion for the success of the IZBs is the proximity to top-level research on the Campus Martinsried / Großhadern. Above all, the new infrastructure measures such as  the Faculty Club G2B (Gateway to Biotech), the IZB Residence CAMPUS AT HOME, the chemistry school Elhardt, the two kindergartens BioKids and BioKids2 as well as the two restaurants SEVEN AND MORE and Café Freshmaker have become the decisive location factor. Successful companies that have emerged from the IZB are, for example, Medigene AG, Morphosys AG, Micromet GmbH (now Amgen AG), Octopharma GmbH and Corimmun (now Janssen-Cilag). More information at www.izb-online.de

 

Press contact IZB:
Susanne Simon, Head of Public Relations
Fördergesellschaft IZB - Innovation and Start-up center for biotechnology
Am Klopferspitz 19, D-82152 Planegg-Martinsried
Tel .: 089/55 279 48-17, Fax: 089/55 279 48-29, Mobile: 0172/86 66 093,
E-Mail: presse@izb-online.de
Website: www.izb-online.de

Go back